Key statistics
On Thursday, Nuvectis Pharma Inc (NVCT:NAQ) closed at 8.80, -23.61% below its 52-week high of 11.52, set on Apr 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.84 |
|---|---|
| High | 9.03 |
| Low | 8.51 |
| Bid | 6.60 |
| Offer | 8.97 |
| Previous close | 8.78 |
| Average volume | 78.31k |
|---|---|
| Shares outstanding | 25.61m |
| Free float | 14.83m |
| P/E (TTM) | -- |
| Market cap | 224.90m USD |
| EPS (TTM) | -1.35 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
- Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
- Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
- Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
- Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
- Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
More ▼
